• Who We Are
    • Executive team
    • Supervisory board
    • Advisory board
  • What We Do
  • Science
    • Behind the Technology
    • Publications and Events
    • Collaboration
  • Business Development
  • News
  • Contact Us
  • English
    • Slovak
Menu
  • Who We Are
    • Executive team
    • Supervisory board
    • Advisory board
  • What We Do
  • Science
    • Behind the Technology
    • Publications and Events
    • Collaboration
  • Business Development
  • News
  • Contact Us
  • English
    • Slovak

Publications and Events

Publications

Novel Prostate Cancer Biomarkers: Aetiology, Clinical Performance and Sensing Applications

Read More »

Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies

Read More »

Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer

Read More »

Glycomics of prostate cancer: updates

Read More »

Detection of N,N-diacetyllactosamine (LacdiNAc) containing free prostate-specific antigen for early stage prostate cancer diagnostics and for identification of castration-resistant prostate cancer patients

Read More »

Analysis of serum glycome by lectin microarrays for prostate cancer patients – a search for aberrant glycoforms

Read More »

Advanced impedimetric biosensor configuration and assay protocol for glycoprofiling of a prostate oncomarker using Au nanoshells with a magnetic core

Read More »

Breast cancer glycan biomarkers: their link to tumour cell metabolism and their perspectives in clinical practice

Read More »

Events

There is no Event

Glycanostics s.r.o.

Kudlákova 7
841 01 Bratislava
Slovakia
Twitter Youtube Linkedin

© Copyright Glycanostcs Ltd. - 2022

We are an innovative start-up company ready to reimagine medicine via early stage, highly accurate and unique cancer diagnostics.

  • Who we are
  • What We Do
  • News
  • Science
  • Contact us
Menu
  • Who we are
  • What We Do
  • News
  • Science
  • Contact us
Glycanostics, s.r.o. currently implements project ProSCAN co-financed by Horizon Europe programme, GA number 190185443 and an APVV project ProGlyCan funded via grant agreement number APVV-20-0476.